Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bortezomib
/ administration & dosage
Drug Resistance, Neoplasm
Female
Humans
Japan
Lenalidomide
/ administration & dosage
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Oligopeptides
/ administration & dosage
Pilot Projects
Prognosis
Prospective Studies
bortezomib
carfilzomib
lenalidomide
multiple myeloma
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
31
05
2021
received:
21
02
2021
accepted:
01
06
2021
pubmed:
15
6
2021
medline:
29
3
2022
entrez:
14
6
2021
Statut:
ppublish
Résumé
Combinatory strategies with carfilzomib (CFZ), a second-generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple myeloma (RRMM) in pivotal clinical trials. However, their effects on patients who were resistance to bortezomib (BTZ) and/or LEN have not been fully evaluated in a daily practice setting. To evaluate the real-world efficacy and safety of CFZ-based treatments; that is, CFZ with LEN plus DEX (KRD therapy) and CFZ with DEX (KD therapy), in Asian patients, we conducted a multicenter pilot prospective observational study in the Kyoto Clinical Hematology Study Group. All 50 patients with RRMM enrolled in this study were treated with CFZ-based treatments between 2017 and 2019. KRD and KD were administered to 31 and 19 patients, respectively. The overall response rates (ORRs) were 80.6% with KRD and 73.7% with KD. Two-year progression-free survival (PFS) and overall survival (OS) were 58.5% and 79.7% with KRD, and 23.1% and 52.6% with KD. By multivariate analysis, refractoriness to BTZ and to LEN were identified as independent unfavorable factors for both PFS and OS. The common non-hematologic AEs included hypertension (42.0%), fever (24.0%), fatigue (24.0%), and infection (16.0%). No serious heart failure was observed. This study is registered as UMIN000025108. This study suggests the need of the development of novel CFZ-containing strategy which can overcome the refractoriness to BTZ and/or LEN, while both KRD and KD were shown to be mostly feasible in Asian patients in a daily practice setting.
Sections du résumé
BACKGROUND
Combinatory strategies with carfilzomib (CFZ), a second-generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple myeloma (RRMM) in pivotal clinical trials. However, their effects on patients who were resistance to bortezomib (BTZ) and/or LEN have not been fully evaluated in a daily practice setting.
AIMS
To evaluate the real-world efficacy and safety of CFZ-based treatments; that is, CFZ with LEN plus DEX (KRD therapy) and CFZ with DEX (KD therapy), in Asian patients, we conducted a multicenter pilot prospective observational study in the Kyoto Clinical Hematology Study Group.
METHODS AND RESULTS
All 50 patients with RRMM enrolled in this study were treated with CFZ-based treatments between 2017 and 2019. KRD and KD were administered to 31 and 19 patients, respectively. The overall response rates (ORRs) were 80.6% with KRD and 73.7% with KD. Two-year progression-free survival (PFS) and overall survival (OS) were 58.5% and 79.7% with KRD, and 23.1% and 52.6% with KD. By multivariate analysis, refractoriness to BTZ and to LEN were identified as independent unfavorable factors for both PFS and OS. The common non-hematologic AEs included hypertension (42.0%), fever (24.0%), fatigue (24.0%), and infection (16.0%). No serious heart failure was observed. This study is registered as UMIN000025108.
CONCLUSION
This study suggests the need of the development of novel CFZ-containing strategy which can overcome the refractoriness to BTZ and/or LEN, while both KRD and KD were shown to be mostly feasible in Asian patients in a daily practice setting.
Identifiants
pubmed: 34124862
doi: 10.1002/cnr2.1476
pmc: PMC8842705
doi:
Substances chimiques
Oligopeptides
0
Bortezomib
69G8BD63PP
carfilzomib
72X6E3J5AR
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1476Subventions
Organisme : Ono Pharmaceutical Co., Ltd
Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1
pubmed: 31160237
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Ann Hematol. 2020 Dec;99(12):2903-2909
pubmed: 32583088
Clin Cancer Res. 2011 May 1;17(9):2734-43
pubmed: 21364033
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Int J Hematol. 2009 Apr;89(3):342-347
pubmed: 19296199
Leukemia. 2018 Feb;32(2):252-262
pubmed: 29257139
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Medsurg Nurs. 2008 Dec;17(6):411-2
pubmed: 19248407
Int J Hematol. 2010 Nov;92(4):579-86
pubmed: 20924731
N Engl J Med. 2015 Jan 8;372(2):142-52
pubmed: 25482145
Semin Oncol. 2016 Dec;43(6):676-681
pubmed: 28061985
Ann Hematol. 2020 Jan;99(1):137-145
pubmed: 31768675
Blood. 2009 Oct 15;114(16):3439-47
pubmed: 19671918
Hematol Oncol. 2021 Feb;39(1):41-50
pubmed: 33085797
Oncotarget. 2018 May 4;9(34):23704-23717
pubmed: 29805768
Expert Rev Hematol. 2014 Feb;7(1):127-41
pubmed: 24350987
Ann Hematol. 2021 Feb;100(2):429-436
pubmed: 33161453
Haematologica. 2006 Jul;91(7):929-34
pubmed: 16818280
Blood Adv. 2020 Nov 10;4(21):5449-5459
pubmed: 33166401
Blood Cancer J. 2017 Jun 30;7(6):e581
pubmed: 28665416
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125
pubmed: 28233151
Int J Hematol. 2019 Oct;110(4):466-473
pubmed: 31388932
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
Crit Rev Oncol Hematol. 2017 May;113:249-255
pubmed: 28427514
Am J Hematol. 2020 Dec;95(12):1486-1494
pubmed: 32804408
JAMA Oncol. 2018 Mar 8;4(3):e174519
pubmed: 29285538
J Clin Oncol. 2018 Mar 10;36(8):728-734
pubmed: 29341834
Blood Cancer J. 2020 May 11;10(5):53
pubmed: 32393732
Lancet Oncol. 2017 Oct;18(10):1327-1337
pubmed: 28843768
Haematologica. 2013 Nov;98(11):1753-61
pubmed: 23935022
Cancer Rep (Hoboken). 2022 Feb;5(2):e1476
pubmed: 34124862
Blood. 2007 Nov 1;110(9):3281-90
pubmed: 17591945
Lancet. 2020 Jan 11;395(10218):132-141
pubmed: 31836199
Leukemia. 2016 Nov;30(11):2198-2207
pubmed: 27118406
Cancer Manag Res. 2019 Apr 02;11:2663-2675
pubmed: 31037034
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):509-518
pubmed: 32482541
Leuk Lymphoma. 2018 Nov;59(11):2557-2569
pubmed: 29465266
Leukemia. 2020 Jul;34(7):1875-1884
pubmed: 32001798
Lancet. 2020 Jul 18;396(10245):186-197
pubmed: 32682484